Q-omics provides the consensus-scored PRSS27 profile across patient tissues and cancer cell-line models. PRSS27 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRSS27 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PRSS27 RNA expression shows 17,219 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where PRSS27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS27 survival associations across molecular data types. PRSS27 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS27 RNA expression–survival associations across cancer types. High PRSS27 expression shows unfavorable associations in ACC, BRCA, MESO, THCA and PRAD, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRSS27 RNA expression.
This table summarizes PRSS27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRSS27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS27 shows lower tumor expression in HNSC and higher tumor expression in KIRC, LUAD, LUSC, KIRP and LIHC. The HNSC box plot shows higher PRSS27 RNA expression in normal versus tumor tissue (log2 FC = −3.880, t-test p < 0.001).
This table shows molecular features associated with PRSS27 in patient tissues and cancer cell lines. In patient samples, PRSS27 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
